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Abstract
Background: The functional significance of moderate riboflavin deficiency as it is currently
assessed is not well understood. Animal and human studies have suggested a role for riboflavin in
the absorption and mobilisation of iron and as such may be important in maintaining haematological
status. Recent National Diet and Nutrition Surveys in the United Kingdom have shown that young
women in particular are at risk of moderate riboflavin deficiency and low iron status.
Methods/Design: A randomised placebo controlled intervention trial was conducted to
investigate the effect of riboflavin supplementation on various measures of haematological status in
a group of moderately riboflavin deficient young women aged 19 to 25 years. Women who were
low milk consumers were initially screened for riboflavin status as assessed by the erythrocyte
glutathione reductase activation coefficient assay (EGRAC). One hundred and twenty three women
with EGRAC values >1.40 were randomised to receive 2 mg, 4 mg riboflavin or placebo for 8
weeks. In addition 36 of these women were randomly allocated to an iron bioavailability study to
investigate the effect of the intervention on the absorption or utilisation of iron using an established
red cell incorporation technique.
Discussion: One hundred and nineteen women completed the intervention study, of whom 36
completed the bioavailability arm. Compliance was 96 ± 6% (mean ± SD). The most effective
recruitment strategy for this gender and age group was e-communication (e-mail and website). The
results of this study will clarify the functional significance of the current biochemical deficiency
threshold for riboflavin status and will inform a re-evaluation of this biochemical threshold.
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Although National Diet and Nutrition Surveys in the
United Kingdom have reported a high prevalence of poor
riboflavin status in certain sections of the population, in
particular adolescent girls (15–18 years) [1] and young
women (19–24 years) [2], the functional significance of
marginal riboflavin deficiency is not well understood.
It has been reported that 95% of adolescent girls (15–18 yr)
and 75% of young women (19–24 yr) in the UK have poor
riboflavin status as measured by the erythrocyte glutath-
ione reductase activation coefficient assay (EGRAC) [1,2].
The EGRAC assay is a well-established measure of ribofla-
vin status and reflects the availability of the FAD cofactor
for glutathione reductase in red blood cells. Although
EGRAC is generally considered to be a functional measure
of riboflavin status, the exact relationship between EGRAC
values and any specific function has not been well estab-
lished. Studies in animal models have highlighted adverse
effects of riboflavin deficiency on various aspects of iron
handling [3,4], but supporting evidence from human stud-
ies is limited. Randomised controlled trials carried out in
riboflavin deficient [5,6] and moderately deficient [7] pop-
ulations have suggested that riboflavin supplementation
might have beneficial effects on measures of haematologi-
cal status in these groups.
Although riboflavin deficiency is highly prevalent among
young women in the UK, and poor iron status, expressed as
low plasma ferritin, shows a moderate prevalence (30%)
[2], it is not known whether there is any causal relationship
and therefore whether improving riboflavin status will have
any beneficial effect on measures of iron status.
Study Aim
The overall aim of the study was to investigate the effect of
a riboflavin supplement on a comprehensive range of hae-
matological parameters and iron bioavailability in a
group of young women with low riboflavin status.
Objectives
The specific objectives of the study were as follows: -
• To recruit women with potentially low riboflavin sta-
tus based on low milk consumption
• To screen recruited women for low riboflavin status
• To randomise women with low riboflavin status to
an eight week placebo-controlled riboflavin interven-
tion trial
• To measure the effect of the intervention on meas-
ures of riboflavin status, other B vitamin status and
iron status
• To measure the effect of the intervention on iron bio-
availability in a subgroup of the women
• To evaluate the diets of the women recruited to the
study
Methods/Design
The study design was a randomised, double-blind, pla-
cebo-controlled, intervention trial in which participants
received one of two daily doses of riboflavin or placebo
over a period of eight weeks and effects on measures of
iron status and iron handling were evaluated. Ethical
approval for the study was granted by the Sheffield Uni-
versity Research Ethics Committee (SMBRER15).
Recruitment
Recruitment started in May 2006. The sample frame con-
sisted of healthy women, aged 19–25 yr, living in the city
of Sheffield, UK. The target was to recruit 200 women to
the screening part of the study, as it was estimated that
66% of the sample would have low riboflavin status,
judged as an EGRAC >1.40. In order to target women with
a low riboflavin status, advertisements were sent out spe-
cifically asking for individuals who consumed less than
250 ml of milk per day since milk and milk products are
the major contributors to riboflavin status in young
women in the UK [2].
Recruitment strategies included approaching women
from an existing volunteer database held at the Human
Nutrition Unit at Sheffield University, a general e-mail
campaign to students and staff at both the Sheffield Hal-
lam University and the University of Sheffield, and the use
of strategically-placed posters in the local area and adver-
tisements in the local newspaper. Leaflets were also
handed out to medical students at lectures. A website was
developed to provide further information and allow pro-
spective volunteers to choose a suitable time for their first
visit to a number of screening clinics held at the unit. The
information sheet was also available for downloading.
Volunteers were offered financial reimbursement for their




• Consumers of less than half a pint of milk (250 ml)
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• Regular blood donors (no donations 3 months
before starting or during the study)
• Regular use of multivitamins or iron supplements
• Diagnosed gastrointestinal problems such as Inflam-
matory Bowel Disease or Coeliac disease
• Haematological disorders
• Haematochromatosis
• Pregnant or lactating
Screening Clinic
The purpose of the screening clinic was four fold: -
1. to establish eligibility on the basis of the inclusion
and exclusion criteria
2. to provide the volunteer with further information
and gain informed consent for the whole study includ-
ing the bioavailability arm
3. to collect the following demographic and health
information by personal interview: -
• date of birth
• contact details
• GP address
• the use of medication
• supplement use
• the presence of known food allergies
• the existence of any medical conditions
• smoking status
• menstrual information – date of last period,
length of cycle and contraceptive usage
4. to collect a 500 μl, non-fasted, finger prick sample
for the measurement of riboflavin status (EGRAC) and
plasma ferritin concentration.
Women with an EGRAC >1.40 were considered to be
moderately riboflavin deficient and were invited to take
part in the intervention study. Those women accepting the
invitation were randomised to receive one of three supple-
ments; 4 mg riboflavin, 2 mg riboflavin or placebo. The
capsules were formulated by Research Products Limited
(RPL, Blackpool) and were suitable for vegetarians and
vegans (gelatin-free and coloured with chlorophyll). The
researchers and participants were blinded to the identity
of each capsule; only the suppliers of the capsules and an
independent third party responsible for the randomisa-
tion knew the identity. The capsules, packed in pots of 60,
were given at the first baseline visit and were sufficient for
the entire intervention allowing 4 spare capsules for any
losses. The riboflavin content in a random sample of each
type of capsule was checked by high performance liquid
chromatography.
Randomisation to treatment
Randomisation was performed by an independent third
party. Treatment codes were generated by ferritin stratifi-
cation in blocks of 3 using a computer generated ran-
domisation schedule. Three ranges of plasma ferritin were
used for stratification; less than 15 ng/ml, 15.1–59.9 ng/
ml and greater than 60 ng/ml. One in four women were
allocated to the bioavailability arm by random sampling
from those in the 4 mg and placebo groups of the inter-
vention.
Protocol for the intervention study
All eligible women were invited to take part in the inter-
vention study (main study). As far as possible the dates for
baseline blood collections were arranged to coincide with
the middle of the menstrual cycle to reduce any effects of
menstrual bleeding on measures of iron status. Once
dates for all clinic visits had been agreed with the volun-
teer, an information pack containing a 4 day food diary,
food portion booklet and a guide to the study was sent by
mail.
Subjects attended the Clinical Research Facility at the
Royal Hallamshire Hospital, Sheffield for all study clinics,
which were held between 8.00 am and 10.00 am. Women
were requested to fast from midnight the previous night.
Frequent contact was maintained by telephone or by
email to remind the volunteers of clinic dates, the require-
ment for a fasted blood sample and the need to complete
food diaries.
Details of clinics
Women attended clinics according to whether they had
been recruited to the intervention study alone or to the
additional bioavailability study. The scheme for the clinic
protocol is given in figure 1.
Intervention study clinics
Baseline Clinic (Week 0)
This was an opportunity to explain the study in more
detail and answer any questions. The height and weight of
each subject were measured. The completed food diaryPage 3 of 8
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Flow diagram for the RIBOFEM studyigure 1





































































BMC Public Health 2009, 9:90 http://www.biomedcentral.com/1471-2458/9/90was returned by the volunteer and the responses discussed
with the researcher. The next food diary was given and
dates agreed for completion prior to the next visit. A fasted
blood samples was taken (15 ml, EDTA vacutainer) for
baseline biochemistry and haematological measure-
ments. Volunteers were given capsules with instructions
for their use.
Interim clinic (Week 4)
A finger prick blood sample was taken (500 μl, EDTA
microvette) for the measurement of EGRAC and ferritin,
to allow the detection of early response to intervention
and to check compliance. The second completed food
diary was collected and discussed.
Post Intervention clinic (Week 8)
A fasted blood sample was collected (15 ml, EDTA vacu-
tainer) for post intervention biochemistry and haemato-
logical measurements. Any remaining capsules were
collected and counted.
Follow-up clinic (Week 12)
A further blood sample was taken (5 ml, EDTA vacu-
tainer) for EGRAC and ferritin measurements to allow
evaluation of the persistence of any response to interven-
tion.
Additional Bioavailability Clinics
A sub-sample (one in four) of the women eligible for the
main intervention study was chosen at random from the
placebo and 4 mg groups to take part in the bioavailability
study, in addition to taking part in the main study. Further
information regarding this aspect of the study, including
food diaries and food portion booklets, was sent to the
women prior to attending the first clinic.
In particular they were advised not to eat red meat for 24
hours or drink alcohol for 12 hours prior to the first clinic.
They were also advised not to take part in any vigorous
exercise for the 24 hours before the clinic.
Women on the bioavailability arm were required to
attend for extra clinics and extra procedures as described
below (see fig. 1).
Bioavailability: first pre-isotope clinic (2 weeks before the intervention 
study)
At this initial clinic, fasted volunteers attended the Clini-
cal Research Facility (CRF) to receive the initial dose of the
stable isotope labelled iron (58Fe = 95.1%). Prior to receiv-
ing this first dose, 5 ml blood were collected into a trace
element free lithium heparin vacutainer and transferred
into acid washed microcentrifuge tubes for background
isotopic analysis. The labelled iron was given in two sepa-
rate 2 mg doses, one with a specially prepared breakfast
and the other with a specially prepared lunch. The isotope
was prepared in aqueous solution (2 mg Fe as a ferrous
sulphate solution per tube) by the Institute of Food
Research (Norwich) and transported to Sheffield on dry
ice. The aliquots of isotope were stored at -20°C until
required. Just prior to administration each dose was
diluted with a lemonade drink and given to the volunteer
within 10 minutes of preparation. The drink containing
the labelled iron was given with a simple breakfast of toast
with jam and dairy-free spread, consumed at 0900 h. Four
hours later the volunteers were given a lunch of pasta and
instant tomato sauce, a plain bread roll and a second
drink containing the 2 mg dose of labelled iron. Beverages
and foods were carefully chosen so as not to contain any
known enhancers or inhibitors of iron absorption. The
beverage was free from phosphoric acid, tannin and vita-
min C according to the manufacturers product description
and the flavour and fizzy nature of the drink masked any
taste of the iron. Additionally meals were chosen on the
basis of a negligible iron or riboflavin content. The pasta
sauce was selected on the basis of negligible vitamin C
content and this was confirmed by enzymatic analysis
using the method described by Vuilleumier [8], (< 1 mg/
meal), using an automated centrifugal analyser (COBAS
BIO Roche Products). Volunteers were allowed to leave
the facility between meals but instructed not to eat, drink
or exercise between the meals or for two hours after the
lunch. Water was permitted ad libitum.
This clinic was also an opportunity to explain the study in
more detail to the bioavailability volunteers, to answer
any questions and to record the height and weight of each
subject. The food diary was collected and the responses
discussed with the researcher. The next food diary was
given and dates agreed for completion prior to the next
visit.
Bioavailability: first post-isotope clinic
This clinic coincided with the baseline visit for the inter-
vention study. In addition to the blood samples taken for
the intervention study afurther fasted blood sample (5 ml,
trace element free heparin vacutainer) was taken for the
bioavailability study.
Bioavailability: second pre-isotope clinic
This clinic coincided with the post intervention clinic of
the main study. At this clinic women repeated the labelled
iron, meal, and blood sampling regimen described above
as well as the blood sampling regimen for the intervention
study.
Bioavailability: second post isotope clinic (2 weeks after the end of 
the intervention)
Fasted blood was collected (5 ml, trace element free lith-
ium heparin vacutainer) and transferred into acid washedPage 5 of 8
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the bioavailability study.
Compliance
The capsules remaining at the end of the study were col-
lected and counted and used as a measure of compliance.
Power Calculation
There is a lack of consistency in the design of studies that
report an improvement in haemoglobin following ribo-
flavin supplementation, in terms of size of dose and dura-
tion of intervention and baseline riboflavin and iron
status. However, Buzina's study [7] is the most relevant in
that the study population was only moderately riboflavin
deficient and less so than the subjects we anticipated
recruiting. This group showed an increase of 0.7 g/dl Hb
over 12 weeks of a modest supplement of 3 mg riboflavin
per day.
Details
We calculated that to achieve a 0.7 g/dl improvement in
Hb in a population with an estimated baseline Hb of 13.5
g/dl (SD 1.05) [2] we required 31 subjects per arm of the
study. This would give a power of 90%. We aimed to
recruit 40 volunteers to each arm, allowing close to 15%
dropout.
Based on an expected level of deficiency in this popula-
tion of 66% it was anticipated that we would need to
screen at least 200 young women.
Power calculation for the bioavailability
It was estimated that 15 subjects per group would be
required to detect a 5% difference between the 4 mg and
placebo intervention groups in iron incorporation into
erythrocytes in response to intervention. This estimate
was based on a mean bioavailabilty of 15% and a SD of
5% [9]with a power of 90% and a significance level of
0.05.
Dietary Analysis
To evaluate any dietary changes during the intervention,
volunteers were asked to complete a four-day food diary
before the baseline visit and again before the interim visit.
The four days included one weekend day. The diary was
sent to the participant prior to the first visit and then dis-
cussed with the researcher at the first visit for checking leg-
ibility, correct entry of food types and portion sizes. The
second diary was given at this visit for completion prior to
the next interim visit and the instructions explained again
if necessary.
The diaries were developed by the Institute of Food
Research, Norwich and modified to include sufficiently
detailed instructions as to make them self-explanatory.
Food portion booklets based on the former Ministry of
Agriculture, Fisheries and Food (MAFF) food atlas [10]
were also provided to assist with estimating portion sizes.
The data from the food diaries were analysed for micronu-
trient and macronutrient content using Windiets Research
software (Robert Gordon University, UK).
Blood collection and laboratory analysis
Blood was collected for the screening and interim visits by
finger prick sampling (500 μl).
Immediately following the clinics, blood samples were
taken to the laboratory, separated by centrifugation and
the red cells washed with PBS and lysed with an equal vol-
ume of water. Haemolysates were stored at -20°C for the
assessment of riboflavin status using the EGRAC assay.
Plasma was stored at -20°C for ferritin analysis.
At the baseline and post intervention visits, blood was col-
lected by venupuncture into vacutainers. A 10 ml blood
sample was collected into EDTA tubes and separated by
centrifugation into plasma and red cells. The red cells were
washed and haemolysed for EGRAC measurement as
before and the plasma divided into aliquots and stored at
-80°C for the measurement of other variables. A further 5
ml blood were collected into a separate EDTA tube and
sent to the Haematology Department at the Royal Hal-
lamshire Hospital for full blood count and zinc protopor-
phyrin (ZPP) measurements.
At the follow up visit a single 5 ml sample was collected
into EDTA tubes for EGRAC and plasma ferritin measure-
ments.
For the bioavailability arm of the study a further 5 ml
blood were collected at the times described in the bioa-
vailability protocol, into heparin trace-element free tubes
and the whole blood aliquoted into 4 acid washed micro-
fuge tubes for sending to the Institute of Food Research,
Norwich for isotopic analysis.
Outcome Variables
Primary Outcome Variables
To assess haematological parameters the following were
measured in the haematology laboratory at the Royal Hal-
lamshire Hospital, Sheffield: red blood cell count, PCV,
MCV, MCHC, haemoglobin and ZPP. ELISA kits were
used to measure plasma ferritin (Spectro Ferritin Kit, ATi
Atlas Ltd. Chichester, UK) and plasma soluble transferrin
receptor (Quantikine DTFR1 – Human sTfR Immu-
noassay, R&D Systems, Abingdon, UK)
Riboflavin status was measured by the EGRAC assay [5]
and plasma flavin concentration measured using an HPLC
kit method (Chromsystems, Munich, Germany).Page 6 of 8
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To adjust for any confounding effects of changes in the
intake of Vitamins C, B2, B6, B12 or folate that might
affect haematological status measurements were made of
these nutrients. Plasma vitamin C was measured by a
fluorometric assay using a COBAS Bio centrifugal analyser
[8]. Plasma pyridoxal phosphate and pyridoxic acid, as
measures of vitamin B6 status, were measured using an
HPLC kit (Chromsystems, Munich, Germany). The rou-
tine clinical chemistry laboratory at the Royal Hallam-
shire Hospital measured plasma vitamin B12, and plasma
folate was measured as 5-methyltetrahydrofolate by iso-
cratic reverse phase HPLC [11].
Because of the documented influence that riboflavin status
can have on plasma homocysteine concentration [12,13]
plasma homocysteine was measured as an additional func-
tional measure of riboflavin status using an iMX autoana-
lyser (Abbott Diagnostics, Maidenhead, Berks, UK).
In order to correct for increases in plasma ferritin as a
result of underlying infection, plasma C-reactive protein
was measured using an ELISA kit (Quantikine DCRP00
Human C-Reactive Protein Immunoassay, R&D Systems,
Abingdon, UK).
Data Analysis
For descriptive statistics baseline values will be analysed
according to randomisation group. Data will be tested for
normality using Shapiro-Wilk and Kolmogorov-Smirnov
tests. Categorical variables will be tested using the Chi
squared test and continuous variables compared across
randomisation groups using ANOVA.
The effects of intervention on all continuous variables will be
analysed by ANOVA. Where ANOVA indicates a significant
difference across the randomisation groups a Scheffe test or
Kruskal-Wallis Multiple Comparison Z-value test will be car-
ried out, as appropriate, to identify where the differences lie.
Spearman Rank Correlations will be conducted to examine
possible associations between selected continuous variables.
Bioavailability data analysis
Statistical analysis will be performed at IFR using R data
analysis software [14]. Standard Linear Regression and
ANOVA models will be used. For all models, regression
diagnostics will be checked to determine if data transfor-
mations, outlier omissions or alternative non-parametric
models are required. Results will be considered significant
if P < 0.05 for all tests.
Initial Findings
Recruitment
Over a period of fifteen months, 256 women were
screened for moderate riboflavin deficiency. From this ini-
tial screening, 145 were eligible for the intervention trial
on the basis of an EGRAC>1.40. This represented 57% of
our screened population. Of these 123 women agreed to
take part in the main study (36 of these were randomly
allocated to the bioavailability arm). In all, 4 women
failed to complete the main study (none of whom, were
in the bioavailability arm).
Compliance
The mean compliance (± SD)of the volunteers as judged
by the number of capsules returned was 96 ± 6%. (range
70–100)
Influence of recruitment to screening on riboflavin status
It was considered possible that the time taken between
screening and starting the intervention trial might influence
dietary change prior to starting the intervention. The
median time that women had to wait before starting the
intervention was 47 days (range 7–240). The main reason
for delay was the coordination of the start of the study with
the menstrual cycle. Other factors included the timing of
vacations and the need to accommodate 4–6 visits over a
period of 12–14 weeks depending on the arm of the study.
The mean EGRAC value for the entire screened popula-
tion (n = 256) was 1.43 ± 0.18.
This is comparable with the EGRAC values reported in the
most recent Diet and Nutrition Survey of adults in the UK
for this age group (mean, 1.45 ± 0.19).
The mean (± SD) EGRAC value of these women recruited
to the intervention study was 1.54 ± 0.14. The mean
EGRAC value at baseline was significantly greater (1.59 ±
0.19) indicating a modest but significant deterioration in
riboflavin status during the waiting period (P = 0.007)
Discussion
Recruitment to the screening and intervention stages of this
study was successfully completed within 16 months. The
recruitment strategies that proved to be the most effective
for this age group were the use of email and a web site,
probably because these are familiar media and in use daily
by this age group. There was also a good response from
posters and leaflets but contact was generally then made via
the web site and email. A short newspaper campaign was
not successful in recruiting volunteers. Constant contact by
email and the frequency of the visits contributed to a low
drop out rate and helped maintain a high compliance rate.
Financial reimbursement was also likely to have been a sig-
nificant factor in obtaining a high recruitment rate and
maintaining involvement in the study.
It was thought that volunteers enrolled into a nutrition
study might modify their diet so as to increase their ribo-
flavin intake during the period from screening until thePage 7 of 8
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start of the intervention study. However the volunteers in
this study showed a deterioration in riboflavin status, evi-
denced by a small but significant increase in the mean
EGRAC value.
The results of this study will provide valuable information
about the effect of a riboflavin supplement on the haema-
tological status of young women with marginal riboflavin
status and help us to understand the functional signifi-
cance of riboflavin deficiency. If an effect is demonstrated
it will form the basis of a discussion to re-evaluate the
EGRAC threshold for riboflavin deficiency.
The randomised controlled trial is now complete and the
statistical analysis underway.
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